Form 4: Zimmer Biomet SVP Sells 1,500 Shares in Pre-Planned Trade

Lori Winkler, SVP and CHRO of Zimmer Biomet Holdings, Inc., executed a pre-planned sale of 1,500 common shares on September 8, 2025.

Summary

• Lori Winkler, Senior Vice President and Chief Human Resources Officer (SVP and CHRO) of Zimmer Biomet Holdings, Inc. (ZBH), reported a transaction.
• The transaction involved the sale of 1,500 shares of common stock.
• The sale occurred on September 8, 2025, at a weighted average price of $104.15 per share.
• Individual sale prices for the 1,500 shares ranged from $104.15 to $104.18 per share.
• Following this transaction, Lori Winkler directly beneficially owns 6,833 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider stock sale, which is a common occurrence and not indicative of specific positive or negative company performance.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled and non-discretionary sale, which often mitigates concerns about insider selling.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for a public company executive and does not inherently reflect broader industry trends or competitive positioning. Such sales are common for compensation and personal financial planning.

Stakeholder Impact

• Shareholders: This routine insider sale is unlikely to have a significant impact on shareholders, especially given its pre-planned nature and relatively small size compared to the company's total outstanding shares.

Key Dates

Recommendation

The sale of 1,500 shares by an SVP, particularly when executed under a Rule 10b5-1 plan, is a routine event for corporate executives and typically does not signal a change in the company's fundamental outlook or warrant a shift in investment recommendation. Investors should continue to evaluate Zimmer Biomet based on its financial performance, strategic initiatives, and market position.

Keywords

Zimmer Biomet, ZBH, Insider Trading, Form 4, Stock Sale, Lori Winkler, 10b5-1 Plan, Corporate Officer